Stay updated with breaking news from Cellular Therapy. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Bristol Myers Squibb receives a positive opinion from the CHMP for the CAR T cell therapy Abecma in previous treatment lines for relapsed and refractory triple class multiple myeloma.)This...
Peter Martin, MD, discusses how to sequence bispecific T-cell engagers and CAR T-cell therapies in the third-line and beyond setting for FL.
CHICAGO, IL / ACCESSWIRE / January 22, 2024 / The American Society for Transplantation and Cellular Therapy (ASTCT), the Association of American Cancer Institutes (AACI), and the Association of Community Cancer Centers (ACCC) recently announced the RECUR initiative. The initiative is a collaboration among these orga...
Older adults without a Part D plan face costs ranging from $180 to $295 per shot.
ASTCT, AACI, and ACCC Launch RECUR Initiative to Enhance Patient Access ...